Artelo Biosciences (ARTL) Income from Continuing Operations (2014 - 2025)
Artelo Biosciences (ARTL) posted quarterly Income from Continuing Operations of 2760000.0 for Q4 2025, up 70.92% year-over-year from 1614821.21 in Q4 2024, and up 13.62% quarter-over-quarter from 3195000.0 in Q3 2025.
Artelo Biosciences (ARTL) Income from Continuing Operations (2014 - 2025) Analysis & Trends
Artelo Biosciences (ARTL) has reported Income from Continuing Operations for 12 consecutive years, with 2760000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Income from Continuing Operations rose 70.92% year-over-year to 2760000.0; the TTM figure through Dec 2025 stood at 12011000.0 (up 24.13% YoY), while the FY2025 annual figure was 19221000.0, down 21.76% from the prior year.
- Income from Continuing Operations rose to 2760000.0 in Q4 2025 per ARTL's latest filing, from 3195000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1203000.0 in Q3 2024 and bottomed at 9490000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 2940030.65 across 5 years, with a median of 2541500.0 in 2021.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations sank 192.9% — and 2025, when it surged 70.92%.
- Artelo Biosciences' Income from Continuing Operations stood at 2551000.0 in 2021, then plunged by 36.06% to 3471000.0 in 2022, then gained by 6.66% to 3240000.0 in 2023, then tumbled by 192.9% to 9490000.0 in 2024, then soared by 70.92% to 2760000.0 in 2025.
- Business Quant data shows ARTL's Income from Continuing Operations at 2760000.0 in Q4 2025, 3195000.0 in Q3 2025, and 3675000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Artelo Biosciences | 107,735.40 | -492,264.60 | - | -2.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.76 Mn |
| Sep 30, 2025 | -3.20 Mn |
| Jun 30, 2025 | -3.68 Mn |
| Mar 31, 2025 | -2.38 Mn |
| Dec 31, 2024 | -9.49 Mn |
| Sep 30, 2024 | -1.20 Mn |
| Jun 30, 2024 | -2.53 Mn |
| Mar 31, 2024 | -2.61 Mn |
| Dec 31, 2023 | -3.24 Mn |
| Sep 30, 2023 | -2.65 Mn |
| Jun 30, 2023 | -1.81 Mn |
| Mar 31, 2023 | -2.30 Mn |
| Dec 31, 2022 | -3.47 Mn |
| Sep 30, 2022 | -2.40 Mn |
| Jun 30, 2022 | -2.49 Mn |
| Mar 31, 2022 | -1.92 Mn |
| Nov 30, 2021 | -2.55 Mn |
| Aug 31, 2021 | -3.78 Mn |
| May 31, 2021 | -2.33 Mn |
| Feb 28, 2021 | -2.02 Mn |